SMT201400001B - Derivati pirazolici usati come antagonisti del recettore CCR4 - Google Patents

Derivati pirazolici usati come antagonisti del recettore CCR4

Info

Publication number
SMT201400001B
SMT201400001B SM201400001T SM201400001T SMT201400001B SM T201400001 B SMT201400001 B SM T201400001B SM 201400001 T SM201400001 T SM 201400001T SM 201400001 T SM201400001 T SM 201400001T SM T201400001 B SMT201400001 B SM T201400001B
Authority
SM
San Marino
Prior art keywords
receptor antagonists
pyrazole derivatives
derivatives used
ccr4 receptor
ccr4
Prior art date
Application number
SM201400001T
Other languages
English (en)
Italian (it)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timothy John Ritchie
Micheal David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SMT201400001B publication Critical patent/SMT201400001B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201400001T 2009-02-26 2014-01-03 Derivati pirazolici usati come antagonisti del recettore CCR4 SMT201400001B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26
PCT/EP2010/052307 WO2010097395A1 (en) 2009-02-26 2010-02-24 Pyrazole derivatives used as ccr4 receptor antagonists

Publications (1)

Publication Number Publication Date
SMT201400001B true SMT201400001B (it) 2014-03-07

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400001T SMT201400001B (it) 2009-02-26 2014-01-03 Derivati pirazolici usati come antagonisti del recettore CCR4

Country Status (31)

Country Link
US (3) US8304446B2 (ko)
EP (1) EP2401270B1 (ko)
JP (1) JP5520969B2 (ko)
KR (1) KR20110128896A (ko)
CN (1) CN102388039B (ko)
AR (1) AR075594A1 (ko)
AU (2) AU2010217629A1 (ko)
BR (1) BRPI1013396A2 (ko)
CA (1) CA2753337A1 (ko)
CL (1) CL2011002103A1 (ko)
CO (1) CO6420342A2 (ko)
DK (1) DK2401270T3 (ko)
DO (1) DOP2011000272A (ko)
EA (1) EA021740B1 (ko)
ES (1) ES2439773T3 (ko)
HK (1) HK1159621A1 (ko)
HR (1) HRP20131174T1 (ko)
IL (1) IL214655A0 (ko)
MA (1) MA33132B1 (ko)
MX (1) MX2011008972A (ko)
NZ (1) NZ594641A (ko)
PE (1) PE20120307A1 (ko)
PL (1) PL2401270T3 (ko)
PT (1) PT2401270E (ko)
RS (1) RS53133B (ko)
SG (1) SG173768A1 (ko)
SI (1) SI2401270T1 (ko)
SM (1) SMT201400001B (ko)
TW (1) TW201041879A (ko)
UY (1) UY32464A (ko)
WO (1) WO2010097395A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
KR20110122746A (ko) 2009-02-26 2011-11-10 에자이 알앤드디 매니지먼트 가부시키가이샤 질소를 함유하는 융합된 헤테로사이클릭 화합물 및 β 아밀로이드 생산 저해제로서의 용도
MX2011006782A (es) 2009-02-26 2011-07-20 Eisai R&D Man Co Ltd Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma.
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
US10179787B2 (en) * 2016-07-29 2019-01-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (en) 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
WO2018188590A1 (en) * 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
US10683280B2 (en) 2018-01-26 2020-06-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062662A1 (fr) * 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
US20130030031A1 (en) 2013-01-31
EA201190142A1 (ru) 2012-05-30
BRPI1013396A2 (pt) 2016-03-29
US20120015932A1 (en) 2012-01-19
MX2011008972A (es) 2011-12-14
AU2016203684A1 (en) 2016-06-23
CL2011002103A1 (es) 2012-02-24
CN102388039A (zh) 2012-03-21
CN102388039B (zh) 2015-07-15
AR075594A1 (es) 2011-04-20
PE20120307A1 (es) 2012-04-04
DOP2011000272A (es) 2011-12-31
EP2401270B1 (en) 2013-10-16
HRP20131174T1 (hr) 2014-01-17
JP5520969B2 (ja) 2014-06-11
NZ594641A (en) 2013-03-28
JP2012518673A (ja) 2012-08-16
US20100216860A1 (en) 2010-08-26
AU2010217629A1 (en) 2011-09-15
UY32464A (es) 2010-09-30
RS53133B (en) 2014-06-30
WO2010097395A1 (en) 2010-09-02
DK2401270T3 (da) 2014-01-13
US8304446B2 (en) 2012-11-06
ES2439773T3 (es) 2014-01-24
PT2401270E (pt) 2014-01-20
US8357716B2 (en) 2013-01-22
HK1159621A1 (en) 2012-08-03
IL214655A0 (en) 2011-09-27
EA021740B1 (ru) 2015-08-31
SG173768A1 (en) 2011-09-29
KR20110128896A (ko) 2011-11-30
US8507543B2 (en) 2013-08-13
CO6420342A2 (es) 2012-04-16
MA33132B1 (fr) 2012-03-01
PL2401270T3 (pl) 2014-03-31
SI2401270T1 (sl) 2014-01-31
CA2753337A1 (en) 2010-09-02
EP2401270A1 (en) 2012-01-04
TW201041879A (en) 2010-12-01

Similar Documents

Publication Publication Date Title
SMT201400001B (it) Derivati pirazolici usati come antagonisti del recettore CCR4
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201400019B (it) Antagonisti del recettore di CGRP
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
SMT201500027B (it) Derivati del benzofurano
SMT201400086B (it) Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi
DK2401269T3 (da) Indolderivater som crth2-receptorantagonister
BR112012010502A2 (pt) derivados de benzimidazol-imidazol
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
UY33109A (es) Nuevos antagonistas del receptor CCR2 y usos de los mismos
CO6801723A2 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaidano
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
DK2799428T3 (da) Glucagon-antagonister
SMT201400080B (it) Derivati di pirazinoossazepina
DK3524230T3 (da) Farmakologiske formuleringer, der omfatter ccr3-antagonister
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
BR112012016923A2 (pt) Derivados de pirazol
ZA201104873B (en) Quinazolinone derivatives useful as vanilloid antagonists
SMT201300020B (it) Derivati di isochinolinone come antagonisti dei recettori nk3
SMT201300077B (it) Derivati di ciclopropilammide diretti al recettoredi istamina H3
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
SMT201500293B (it) Antagonisti del recettore toll-like 3
EP2378877A4 (en) IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS